ArticleOncotarget2017

Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study.

Jun-Te Hsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.